HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
14.67
-0.19 (-1.28%)
Oct 28, 2025, 4:00 PM EDT - Market closed
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
$332,522
Profits / Employee
$257,803
Market Cap
2.52B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | 1,280 | 427 | 50.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HCM News
- 14 days ago - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - GlobeNewsWire
- 16 days ago - HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewsWire
- 27 days ago - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 - GlobeNewsWire
- 6 weeks ago - Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 - GlobeNewsWire
- 7 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewsWire
- 2 months ago - HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewsWire
- 2 months ago - HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript - Seeking Alpha